Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Anaphylaxis and anaphylactoid reactions associated with the insertion of peripherally inserted central catheters: A multiyear comparative retrospective cohort study.

Thornton CS, Dumanski J, Margherit C, Vaz-Gonsalves S, McDiarmid S, Parkins MD, Conly JM.

Infect Control Hosp Epidemiol. 2019 Nov;40(11):1215-1221. doi: 10.1017/ice.2019.237.

PMID:
31591954
2.

Epidemiology and Outcome Determinants of Staphylococcus aureus Bacteremia Revisited: A Population-Based Study.

Lam JC, Gregson DB, Robinson S, Somayaji R, Conly JM, Parkins MD.

Infection. 2019 Jul 3. doi: 10.1007/s15010-019-01330-5. [Epub ahead of print]

PMID:
31270751
3.

A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome.

Woo TE, Lim R, Heirali AA, Acosta N, Rabin HR, Mody CH, Somayaji R, Surette MG, Sibley CD, Storey DG, Parkins MD.

Sci Rep. 2019 May 3;9(1):6871. doi: 10.1038/s41598-019-42862-y.

4.

Specificity in the Susceptibilities of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus Clinical Isolates to Six Metal Antimicrobials.

Gugala N, Vu D, Parkins MD, Turner RJ.

Antibiotics (Basel). 2019 May 1;8(2). pii: E51. doi: 10.3390/antibiotics8020051.

5.

Cytomegalovirus: an unrecognised potential contributor to cystic fibrosis disease progression?

Parkins MD, Ramos KJ, Goss CH, Somayaji R.

Eur Respir J. 2019 Apr 25;53(4). pii: 1801727. doi: 10.1183/13993003.01727-2018. Print 2019 Apr. No abstract available.

PMID:
30956206
6.

The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.

Heirali AA, Acosta N, Storey DG, Workentine ML, Somayaji R, Laforest-Lapointe I, Leung W, Quon BS, Berthiaume Y, Rabin HR, Waddell BJ, Rossi L, Surette MG, Parkins MD.

J Cyst Fibros. 2019 Mar 8. pii: S1569-1993(19)30028-1. doi: 10.1016/j.jcf.2019.02.010. [Epub ahead of print]

PMID:
30857926
7.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
8.

Recurrent Herpes Simplex Virus Encephalitis After Epilepsy Surgery.

Arnold A, Parkins MD, Hamilton LE, Hader W, Federico P.

Can J Neurol Sci. 2019 Mar;46(2):261-263. doi: 10.1017/cjn.2018.385. Epub 2019 Jan 22. No abstract available.

PMID:
30665474
9.

Incidence and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study.

Stokes W, Parkins MD, Parfitt ECT, Ruiz JC, Mugford G, Gregson DB.

Clin Infect Dis. 2019 Aug 30;69(6):963-969. doi: 10.1093/cid/ciy1000.

PMID:
30476003
10.

Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Parkins MD, Somayaji R, Waters VJ.

Clin Microbiol Rev. 2018 Aug 29;31(4). pii: e00019-18. doi: 10.1128/CMR.00019-18. Print 2018 Oct. Review.

11.

Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis.

Acosta N, Heirali A, Somayaji R, Surette MG, Workentine ML, Sibley CD, Rabin HR, Parkins MD.

Thorax. 2018 Nov;73(11):1016-1025. doi: 10.1136/thoraxjnl-2018-211510. Epub 2018 Aug 22.

PMID:
30135091
12.

Secreted Phosphatase and Deoxyribonuclease Are Required by Pseudomonas aeruginosa To Defend against Neutrophil Extracellular Traps.

Wilton M, Halverson TWR, Charron-Mazenod L, Parkins MD, Lewenza S.

Infect Immun. 2018 Aug 22;86(9). pii: e00403-18. doi: 10.1128/IAI.00403-18. Print 2018 Sep.

13.

Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis.

Woo TE, Lim R, Surette MG, Waddell B, Bowron JC, Somayaji R, Duong J, Mody CH, Rabin HR, Storey DG, Parkins MD.

ERJ Open Res. 2018 Jun 18;4(2). pii: 00162-2017. doi: 10.1183/23120541.00162-2017. eCollection 2018 Apr.

14.

Meropenem potentiation of aminoglycoside activity against Pseudomonas aeruginosa: involvement of the MexXY-OprM multidrug efflux system.

Poole K, Gilmour C, Farha MA, Parkins MD, Klinoski R, Brown ED.

J Antimicrob Chemother. 2018 May 1;73(5):1247-1255. doi: 10.1093/jac/dkx539.

PMID:
29420743
15.

Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Skolnik K, Nguyen A, Thornton CS, Waddell B, Williamson T, Rabin HR, Parkins MD.

BMC Infect Dis. 2017 Oct 2;17(1):660. doi: 10.1186/s12879-017-2729-6.

16.

Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.

Mikalauskas A, Parkins MD, Poole K.

J Antimicrob Chemother. 2017 Dec 1;72(12):3349-3352. doi: 10.1093/jac/dkx296.

17.

The Evolving Cystic Fibrosis Microbiome: A Comparative Cohort Study Spanning 16 Years.

Acosta N, Whelan FJ, Somayaji R, Poonja A, Surette MG, Rabin HR, Parkins MD.

Ann Am Thorac Soc. 2017 Aug;14(8):1288-1297. doi: 10.1513/AnnalsATS.201609-668OC.

PMID:
28541746
18.

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.

Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, Rabin HR, Whelan FJ, Surette MG, Parkins MD.

Microbiome. 2017 May 5;5(1):51. doi: 10.1186/s40168-017-0265-7.

19.

Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin HR, Surette MG, Parkins MD.

J Clin Microbiol. 2017 Jul;55(7):2074-2085. doi: 10.1128/JCM.02556-16. Epub 2017 Apr 26.

20.

Albendazole-responsive disseminated Tubulinosema acridophagus in a patient with chronic lymphocytic leukaemia.

Connors WJ, Carson JA, Chan WW, Parkins MD.

Clin Microbiol Infect. 2017 Sep;23(9):684-685. doi: 10.1016/j.cmi.2017.04.002. Epub 2017 Apr 9. No abstract available.

21.

Acute dental infections managed in an outpatient parenteral antibiotic program setting: prospective analysis and public health implications.

Connors WJ, Rabie HH, Figueiredo RL, Holton DL, Parkins MD.

BMC Infect Dis. 2017 Mar 9;17(1):202. doi: 10.1186/s12879-017-2303-2.

22.

Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis.

Whelan FJ, Heirali AA, Rossi L, Rabin HR, Parkins MD, Surette MG.

PLoS One. 2017 Mar 2;12(3):e0172811. doi: 10.1371/journal.pone.0172811. eCollection 2017.

23.

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

Strug LJ, Gonska T, He G, Keenan K, Ip W, Boëlle PY, Lin F, Panjwani N, Gong J, Li W, Soave D, Xiao B, Tullis E, Rabin H, Parkins MD, Price A, Zuberbuhler PC, Corvol H, Ratjen F, Sun L, Bear CE, Rommens JM.

Hum Mol Genet. 2016 Oct 15;25(20):4590-4600. doi: 10.1093/hmg/ddw290.

24.

Effect of freezing sputum on Pseudomonas aeruginosa population heterogeneity.

Poonja A, Heirali A, Workentine M, Storey DG, Somayaji R, Rabin HR, Surette MG, Parkins MD.

J Cyst Fibros. 2017 May;16(3):353-357. doi: 10.1016/j.jcf.2017.01.004. Epub 2017 Jan 24.

25.

Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis.

Syed SA, Whelan FJ, Waddell B, Rabin HR, Parkins MD, Surette MG.

Ann Am Thorac Soc. 2016 Dec;13(12):2132-2142.

PMID:
27925791
26.

Virulence Adaptations of Pseudomonas aeruginosa Isolated from Patients with Non-Cystic Fibrosis Bronchiectasis.

Woo TE, Duong J, Jervis NM, Rabin HR, Parkins MD, Storey DG.

Microbiology. 2016 Nov 8. doi: 10.1099/mic.0.000393. [Epub ahead of print]

27.

Long-term clinical outcomes of 'Prairie Epidemic Strain' Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Somayaji R, Lam JC, Surette MG, Waddell B, Rabin HR, Sibley CD, Purighalla S, Parkins MD.

Thorax. 2017 Apr;72(4):333-339. doi: 10.1136/thoraxjnl-2015-208083. Epub 2016 Sep 28.

PMID:
27682327
28.

Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

Wilton M, Wong MJQ, Tang L, Liang X, Moore R, Parkins MD, Lewenza S, Dong TG.

Infect Immun. 2016 Jul 21;84(8):2355-2361. doi: 10.1128/IAI.00233-16. Print 2016 Aug.

29.

Understanding the natural history and clinical implications of airways infections in CF - Moving beyond the classics.

Parkins MD, Surette MG.

J Cyst Fibros. 2016 May;15(3):270-1. doi: 10.1016/j.jcf.2016.03.001. Epub 2016 Mar 29. No abstract available.

30.

Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections.

Heirali A, McKeon S, Purighalla S, Storey DG, Rossi L, Costilhes G, Drews SJ, Rabin HR, Surette MG, Parkins MD.

PLoS One. 2016 Feb 9;11(2):e0148534. doi: 10.1371/journal.pone.0148534. eCollection 2016.

31.

Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Workentine M, Poonja A, Waddell B, Duong J, Storey DG, Gregson D, Somayaji R, Rabin HR, Surette MG, Parkins MD.

J Clin Microbiol. 2016 Feb;54(2):489-91. doi: 10.1128/JCM.02603-15. Epub 2015 Dec 9.

32.

Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation.

Pritchard J, Thakrar MV, Somayaji R, Surette MG, Rabin HR, Helmersen D, Lien D, Purighalla S, Waddell B, Parkins MD.

J Cyst Fibros. 2016 May;15(3):392-9. doi: 10.1016/j.jcf.2015.11.004. Epub 2015 Dec 3.

33.

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.

Skolnik K, Nguyen A, Somayaji R, Thornton CS, Waddell B, Surette MG, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 Dec 12;15:161. doi: 10.1186/s12890-015-0157-1.

34.

Phenotypic and Genotypic Comparison of Epidemic and Non-Epidemic Strains of Pseudomonas aeruginosa from Individuals with Cystic Fibrosis.

Duong J, Booth SC, McCartney NK, Rabin HR, Parkins MD, Storey DG.

PLoS One. 2015 Nov 23;10(11):e0143466. doi: 10.1371/journal.pone.0143466. eCollection 2015.

35.

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa.

Somayaji R, Waddell B, Workentine ML, Surette MG, Brager NP, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 Nov 5;15:138. doi: 10.1186/s12890-015-0116-x.

36.

Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients.

Thornton CS, Grinwis ME, Sibley CD, Parkins MD, Rabin HR, Surette MG.

J Med Microbiol. 2015 Nov;64(11):1375-86. doi: 10.1099/jmm.0.000172. Epub 2015 Sep 25.

PMID:
26408040
37.

Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study.

Thornton CS, Brown EL, Alcantara J, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 May 2;15:49. doi: 10.1186/s12890-015-0041-z.

38.

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.

Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD.

BMC Infect Dis. 2015 Mar 22;15:145. doi: 10.1186/s12879-015-0856-5.

39.

Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis.

Parkins MD, Floto RA.

J Cyst Fibros. 2015 May;14(3):293-304. doi: 10.1016/j.jcf.2015.03.012. Epub 2015 Apr 14. Review.

40.

Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.

Somayaji R, Parkins MD.

Ther Deliv. 2015 Feb;6(2):121-37. doi: 10.4155/tde.14.94. Review.

PMID:
25690082
41.

Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study.

Billington EO, Phang SH, Gregson DB, Pitout JD, Ross T, Church DL, Laupland KB, Parkins MD.

Int J Infect Dis. 2014 Sep;26:76-82. doi: 10.1016/j.ijid.2014.02.012. Epub 2014 May 9.

42.

Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, Mody CH, Workentine ML, Storey DG, Surette MG, Rabin HR.

J Clin Microbiol. 2014 Apr;52(4):1127-35. doi: 10.1128/JCM.03218-13. Epub 2014 Jan 22.

43.

Granulomatous PJP presenting as a solitary lung nodule in an immune competent female.

Lam J, Kelly MM, Leigh R, Parkins MD.

Respir Med Case Rep. 2013 Oct 26;11:4-6. doi: 10.1016/j.rmcr.2013.10.002. eCollection 2014.

44.

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Lam J, Vaughan S, Parkins MD.

Clin Med Insights Circ Respir Pulm Med. 2013 Nov 13;7:61-77. doi: 10.4137/CCRPM.S10592. Review.

45.

Metastatic bladder cancer presenting with persistent hematuria in young man with cystic fibrosis.

Patel P, Rabin HR, Vickers MM, Parkins MD.

Case Rep Pulmonol. 2013;2013:831871. doi: 10.1155/2013/831871. Epub 2013 May 14.

46.

Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient.

Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, Surette MG.

PLoS One. 2013;8(4):e60225. doi: 10.1371/journal.pone.0060225. Epub 2013 Apr 3.

47.

Population-based assessment of the incidence, risk factors, and outcomes of anaerobic bloodstream infections.

Ngo JT, Parkins MD, Gregson DB, Pitout JD, Ross T, Church DL, Laupland KB.

Infection. 2013 Feb;41(1):41-8. doi: 10.1007/s15010-012-0389-4. Epub 2013 Jan 5.

PMID:
23292663
48.

Pyrosequencing reveals the complex polymicrobial nature of invasive pyogenic infections: microbial constituents of empyema, liver abscess, and intracerebral abscess.

Sibley CD, Church DL, Surette MG, Dowd SE, Parkins MD.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2679-91. Epub 2012 Apr 28.

PMID:
22544344
49.

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Parkins MD, Elborn JS.

Expert Rev Respir Med. 2011 Oct;5(5):609-22. doi: 10.1586/ers.11.56. Review.

PMID:
21955231
50.

Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.

Parkins MD, Rendall JC, Elborn JS.

Chest. 2012 Feb;141(2):485-493. doi: 10.1378/chest.11-0917. Epub 2011 Aug 11.

PMID:
21835906

Supplemental Content

Loading ...
Support Center